The global hospital acquired infections therapeutic market size is expected to reach USD 12.5 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 2.4% from 2020 to 2027. The high prevalence of HAIs, rise in approval and launch of new drugs, and growing hospitalization due to the rise in prevalence of chronic diseases are driving the market.
According
to the data published by the New York State Department of Health in November
2019, around 160 hospitals in New York reported total cases of around 1,139
colon SSIs out of 19,732 procedures in 2018, a rate of 5.8 infections per 100
procedures. The same source also states that in 2018, around 15,310 cases of
Clostridioides difficile infections (CDI) were reported in acute care hospitals
located in New York. Such, high prevalence of hospital-acquired infections is
anticipated to significantly raise the demand for its treatment therapies and
support the HAIs therapeutics market growth over the forecast period.
Furthermore,
key players in the market are involved in extensive R&D initiatives for the
development and indication expansion of its already approved drugs for HAI
treatment. For instance, in February 2018, the FDA approved Allergan plc’s
supplemental New Drug Application (sNDA) and expanded the approval of Avycaz
(ceftazidime and avibactam) to include the treatment of HABP/VABP and
hospital-acquired bacterial pneumonia.
Full Research Report On Hospital Acquired Infections Therapeutic Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/hospital-acquired-infections-therapeutic-market
Hospital Acquired
Infections Therapeutic Market Report Highlights
- Antibacterial
drugs dominated the drug class segment in 2019, owing to the high adoption
of antibiotics as the first line of treatment for hospital-acquired
infections (HAIs)
- The surgical
site infections (SSIs) segment held the largest market share in 2019 due
to the rising number of surgical procedures and subsequent rising cases of
SSIs
- The urinary
tract infections (UTIs) segment is anticipated to show the fastest growth
rate during the forecast period owing to the growing number of UTI cases
and rising awareness among people about the disease condition in
less-developed countries
- The introduction
of novel drugs by key players, for instance, Merck to treat
ventilator-associated pneumonia has led to a high growth of the market
- The high
prevalence of HAIs in the European countries is the major factor
significantly driving the demand for its medications in this region
- Growing
awareness levels about various risk factors associated with HAIs in ICU
and other emergency care settings is expected to propel market growth in
the Asia Pacific region
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/hospital-acquired-infections-therapeutic-market/request/rs1
Hospital Acquired
Infections Therapeutic Market Segmentation
Grand View Research has
segmented the global hospital acquired infections therapeutic market report on
the basis of drug class, infection type, and region:
HAIs Therapeutics
Drug Class Outlook (Revenue, USD Million, 2016 - 2027)
- Antibacterial Drugs
- Cell Wall Synthesis Inhibitors
- Protein Synthesis Inhibitors
- Others
- Antiviral Drugs
- Antifungal Drugs
HAIs
Therapeutics Infection Type Outlook (Revenue, USD Million, 2016 -
2027)
- Urinary Tract Infections
- Ventilator-associated Pneumonia
- Surgical Site Infections
- Bloodstream Infections
- Other Hospital Infections
HAIs Therapeutics
Regional Outlook (Revenue, USD Million, 2016 - 2027)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Asia Pacific
- Japan
- China
- India
- South Korea
- Singapore
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
List of Key
Players of Hospital Acquired
Infections Therapeutic Market
- Merck & Co., Inc.
- Pfizer Inc.
- Bayer AG
- GlaxoSmithKline Plc.
- Daiichi Sankyo Company, Limited
- AbbVie Inc.
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- Allergan Plc.
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment